Back to Report Store Home

Influenza A Viral Infections Drug Development Pipeline Review, 2018

  • Published: Apr-2018
  • Report Code: GBIHC032IDB
  • Report Format: pdf

Description

This report provides an overview of the pipeline landscape for influenza A viral infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A H3N2, H1N1, H5N1 and H7N9 subtype infections, and features dormant and discontinued products.

Influenza is an acute infection of the respiratory tract that predominately affects the nose, throat and bronchi, and less commonly the lungs. Influenza viruses have a single-stranded segmented RNA genome. They belong to the family Orthomyxoviridae, and are categorized into three genera based on their core proteins – A, B and C. Influenza A and B viruses are responsible for the majority of symptomatic cases of influenza in humans.

Influenza A viruses can be further categorized based on their expression of two viral surface proteins: hemagglutinin (H); and neuraminidase (N). These viruses are known to have high mutation rates, with frequent changes to the viral protein structure.

Scope

  • Which companies are the most active within the pipeline for influenza A viral infections?

  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

  • What are the most important R&D milestones and data publications to have happened within this field?

Reasons To Buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards